Using a novel drug to target the STING pathway reprograms immune responses towards glioblastoma, providing a potential therapy for non-responsive patients.
Targeting the STING pathway activates the immune system against glioblastoma, which usually recruits immunosuppressive cells to support tumor growth.
Collection
[
|
...
]